-
公开(公告)号:US20210106607A1
公开(公告)日:2021-04-15
申请号:US17065242
申请日:2020-10-07
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: MASATO YOSHIKAWA , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , C07H21/00 , C07H21/02 , A61K47/68 , A61K31/7076
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号:US09382188B2
公开(公告)日:2016-07-05
申请号:US14377953
申请日:2013-02-12
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Seiji Miwatashi , Hideo Suzuki , Tomohiro Okawa , Yasufumi Miyamoto , Takeshi Yamasaki , Yuko Hitomi , Yasuhiro Hirata , Akito Shibuya
IPC: C07C59/135 , C07D405/14 , C07C255/46 , C07D309/06 , C07D231/12 , C07D333/38 , C07D401/12 , C07D239/26 , C07D239/34 , C07C317/44 , C07C229/34 , C07C233/47 , C07D271/10 , C07D277/24 , C07C255/37 , C07D285/12 , C07D213/30 , C07D213/55 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/69 , C07C59/68 , C07C59/70 , C07C59/72 , C07D213/12 , C07C309/65 , C07C309/66 , C07C311/21 , C07C323/56 , C07C235/34 , C07C255/41
CPC classification number: C07C59/135 , C07C59/68 , C07C59/70 , C07C59/72 , C07C229/34 , C07C233/47 , C07C235/34 , C07C255/37 , C07C255/41 , C07C255/46 , C07C309/65 , C07C309/66 , C07C311/21 , C07C317/44 , C07C323/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/12 , C07D213/30 , C07D213/55 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/69 , C07D231/12 , C07D239/26 , C07D239/34 , C07D271/10 , C07D277/24 , C07D285/12 , C07D309/06 , C07D333/38 , C07D401/04 , C07D401/12 , C07D405/12 , C07D405/14
Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
-
公开(公告)号:US20210137962A9
公开(公告)日:2021-05-13
申请号:US16185258
申请日:2018-11-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Yoshitomi , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Yoshihisa Nakada , Michiyo Mochizuki
IPC: A61K31/7084 , A61P35/00 , A61K47/68 , A61K31/7076
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号:US09321757B2
公开(公告)日:2016-04-26
申请号:US14533326
申请日:2014-11-05
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masato Yoshida , Kazuaki Takami , Yusuke Tominari , Zenyu Shiokawa , Akito Shibuya , Yusuke Sasaki , Tony Gibson , Terufumi Takagi
IPC: C07D401/14 , C07D487/04 , C07D417/14 , C07D487/10 , A61P37/00 , C07D403/14 , A61K31/4155 , C07D413/14 , C07D409/14 , C07D405/14 , C07D401/04 , A61K9/06 , A61K9/20 , A61K9/48
CPC classification number: C07D413/14 , A61K9/06 , A61K9/2018 , A61K9/2054 , A61K9/4858 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107 , C07D495/04
Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物,其可用于预防或治疗炎性疾病,自身免疫性疾病,骨关节炎性退行性疾病,肿瘤性疾病等,以及含有它们的药物。 本发明涉及由式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐。
-
公开(公告)号:US12171777B2
公开(公告)日:2024-12-24
申请号:US18310467
申请日:2023-05-01
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61K31/7076 , A61K47/68 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号:US11666594B2
公开(公告)日:2023-06-06
申请号:US17065242
申请日:2020-10-07
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Yusuke Sasaki , Masanori Okaniwa , Tsuneo Oda , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Shumpei Murata , Atsutoshi Okabe , Yoshihisa Nakada , Michiyo Mochizuki , Brian Scott Freeze , Taisuke Tawaraishi , Yasufumi Wada , Paul D. Greenspan
IPC: A61K31/7084 , A61P35/00 , C07H21/00 , C07H21/02 , A61K47/68 , A61K31/7076
CPC classification number: A61K31/7084 , A61K31/7076 , A61K47/6807 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号:US09890145B2
公开(公告)日:2018-02-13
申请号:US15137161
申请日:2016-04-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masato Yoshida , Kazuaki Takami , Yusuke Tominari , Zenyu Shiokawa , Akito Shibuya , Yusuke Sasaki , Tony Gibson , Terufumi Takagi
IPC: C07D401/14 , C07D487/04 , C07D417/14 , C07D487/10 , A61P37/00 , C07D403/14 , A61K31/4155 , C07D413/14 , C07D401/04 , C07D409/14 , C07D405/14 , A61K9/06 , A61K9/20 , A61K9/48 , C07D403/04 , C07D471/04 , C07D471/10 , C07D491/107 , C07D495/04
CPC classification number: C07D413/14 , A61K9/06 , A61K9/2018 , A61K9/2054 , A61K9/4858 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107 , C07D495/04
Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号:US20150018422A1
公开(公告)日:2015-01-15
申请号:US14377953
申请日:2013-02-12
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Seiji Miwatashi , Hideo Suzuki , Tomohiro Okawa , Yasufumi Miyamoto , Takeshi Yamasaki , Yuko Hitomi , Yasuhiro Hirata , Akito Shibuya
IPC: C07C59/135
CPC classification number: C07C59/135 , C07C59/68 , C07C59/70 , C07C59/72 , C07C229/34 , C07C233/47 , C07C235/34 , C07C255/37 , C07C255/41 , C07C255/46 , C07C309/65 , C07C309/66 , C07C311/21 , C07C317/44 , C07C323/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/12 , C07D213/30 , C07D213/55 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/69 , C07D231/12 , C07D239/26 , C07D239/34 , C07D271/10 , C07D277/24 , C07D285/12 , C07D309/06 , C07D333/38 , C07D401/04 , C07D401/12 , C07D405/12 , C07D405/14
Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
-
公开(公告)号:US11186565B2
公开(公告)日:2021-11-30
申请号:US16499432
申请日:2018-03-29
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Seiji Miwatashi , Yasufumi Miyamoto , Koji Watanabe , Yayoi Nakayama , Yuko Hitomi , Jumpei Aida , Nobuyuki Takakura , Hideki Furukawa , Naoyoshi Noguchi , Yasuhiro Hirata , Kazuaki Takami , Norihito Tokunaga , Tomohiro Okawa , Akito Shibuya , Shizuo Kasai , Toshitake Kobayashi , Tsuyoshi Maekawa
IPC: C07D401/12 , C07C59/72 , C07D211/22 , C07D213/64 , C07D401/10 , C07D401/14 , C07D413/10
Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
-
公开(公告)号:US10980825B2
公开(公告)日:2021-04-20
申请号:US16185258
申请日:2018-11-09
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masato Yoshikawa , Morihisa Saitoh , Taisuke Kato , Yayoi Nakayama , Tomohiro Seki , Yasuo Nakagawa , Yusuke Tominari , Masaki Seto , Akito Shibuya , Kosuke Hidaka , Zenyu Shiokawa , Yoshihisa Nakada , Michiyo Mochizuki
IPC: A61K31/7084 , A61K31/7076 , A61K47/68 , A61P35/00 , C07H21/00 , C07H21/02
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
-
-
-
-
-
-
-
-
-